SINGLE-LAYER ORAL DOSE OF NEURO-ATTENUATING KETAMINE
The present invention is directed to oral neuro-attenuating ketamine (NAKET) tablet formulations, and methods of administration, which ensure the steady release of a therapeutically effective concentration of ketamine from an oral tablet without neurologically toxic spikes in ketamine concentration....
Saved in:
Main Authors | , |
---|---|
Format | Patent |
Language | English |
Published |
20.08.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present invention is directed to oral neuro-attenuating ketamine (NAKET) tablet formulations, and methods of administration, which ensure the steady release of a therapeutically effective concentration of ketamine from an oral tablet without neurologically toxic spikes in ketamine concentration. In particular, the present invention provides single layer oral tablet formulation of NAKET. In a specific embodiment, the NAKET tablet formulation, and methods of administration provide steady administration of NAKET to a subject for 24 hours or greater, for example, up to 36 hours, after a single administration event. |
---|---|
Bibliography: | Application Number: US202016868444 |